Adaptive Neoadjuvant Therapy for Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new treatment approach for esophageal cancer that includes chemotherapy and immunotherapy before surgery. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your esophageal cancer must be a certain type called squamous cell carcinoma, at specific stages.
- You must be healthy enough for surgery, with good organ function (kidneys, liver, blood counts).
- You cannot have had any prior cancer treatment for this esophageal cancer.
- You must be willing to provide a tumor tissue sample for analysis.
- You cannot have certain other medical conditions like active hepatitis B, unstable heart disease, or severe lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests giving chemotherapy with immunotherapy, or chemotherapy with radiation, before surgery for esophageal cancer. The goal is to see which approach is better at shrinking the tumor and improving outcomes.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.